Catalina Villota-Eraso
Overview
Explore the profile of Catalina Villota-Eraso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Matteo A, Di Donato S, Smerilli G, Becciolini A, Camarda F, Cauli A, et al.
Arthritis Rheumatol
. 2024 Aug;
77(1):22-33.
PMID: 39165013
Objective: The study objectives were (i) to explore the agreement between the Outcome Measures in Rheumatology (OMERACT) ultrasound lesions of enthesitis and physical examination in assessing enthesitis in patients with...
2.
Di Matteo A, Smerilli G, Di Donato S, Liu A, Becciolini A, Camarda F, et al.
Ann Rheum Dis
. 2024 Mar;
83(7):847-857.
PMID: 38443140
Objectives: To assess, in spondyloarthritis (SpA), the discriminative value of the Outcome Measures in Rheumatology (OMERACT) ultrasound lesions of enthesitis and their associations with clinical features in this population. Methods:...
3.
Garcia-Montoya L, Villota-Eraso C, Md Yusof M, Vital E, Emery P
Lancet Rheumatol
. 2024 Jan;
2(8):e497-e509.
PMID: 38273611
B-cell depletion therapy is an effective option for the treatment of rheumatoid arthritis but often does not result in complete B-cell depletion. Complete B-cell depletion after rituximab treatment is associated...
4.
Di Matteo A, Moscioni E, Lommano M, Cipolletta E, Smerilli G, Farah S, et al.
Front Med (Lausanne)
. 2023 Feb;
9:1090468.
PMID: 36733934
Objectives: To investigate the inter/intra-reliability of ultrasound (US) muscle echogenicity in patients with rheumatic diseases. Methods: Forty-two rheumatologists and 2 radiologists from 13 countries were asked to assess US muscle...
5.
Salaffi F, Carotti M, Di Matteo A, Ceccarelli L, Farah S, Villota-Eraso C, et al.
Radiol Med
. 2022 Sep;
127(11):1277-1291.
PMID: 36125609
Sarcopenia is characterized by loss of muscle mass, altered muscle composition, fat and fibrous tissue infiltration, and abnormal innervation, especially in older individuals with immune-mediated rheumatic diseases (IMRDs). Several techniques...
6.
Di Matteo A, Smerilli G, Cipolletta E, Wakefield R, De Angelis R, Risa A, et al.
Rheumatology (Oxford)
. 2022 Mar;
61(12):4775-4785.
PMID: 35333315
Objectives: The objectives of this study were (1) to explore US findings for muscle mass, muscle quality and muscle stiffness in SLE patients and healthy subjects; (2) to investigate the...
7.
Garcia-Montoya L, Nam J, Duquenne L, Villota-Eraso C, Di Matteo A, Hartley C, et al.
Arthritis Res Ther
. 2022 Jan;
24(1):26.
PMID: 35042555
Background: Musculoskeletal (MSK) symptoms are among the commonest reasons for primary care assessments; however, few individuals will be diagnosed with an inflammatory arthritis (IA) within the following year. The purpose...
8.
Londono J, Santos A, Rueda J, Calvo-Paramo E, Burgos-Vargas R, Vargas-Alarcon G, et al.
RMD Open
. 2020 Sep;
6(2).
PMID: 32917832
Objective: To determine the association between endoplasmic reticulum aminopeptidase (ERAP)1 and ERAP2 single-nucleotide polymorphisms (SNPs) and human leukocyte antigens (HLA)-B27+ or HLA-B15+ patients with spondyloarthritis (SpA). Methods: 104 patients with...
9.
Londono J, Saldarriaga E, Rueda J, Giraldo-Bustos R, Angarita J, Restrepo L, et al.
Biomed Rep
. 2020 Aug;
13(4):34.
PMID: 32793348
Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA). However, over time, ~40% of patients may experience therapeutic failure or drug toxicity....
10.
Fernandez-Avila D, Rondon-Carvajal J, Villota-Eraso C, Gutierrez-Davila J, Contreras-Villamizar K
Rheumatol Int
. 2020 Jun;
40(8):1283-1290.
PMID: 32564160
Vasculitides associated with anti-neutrophil cytoplasmic antibodies are heterogeneous, systemic, low prevalence and high morbidity and mortality entities. They include granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. In...